// App-Quantinova.ai

291 : Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors

Researchers

Presenter

  • Fabrice Barlesi

Principal Investigators

  • Kristoffer Staal Rohrberg

  • Cinta Hierro

  • Aurelien Marabelle

  • Albiruni Abdul Razak

  • Luis Teixeira

  • Valentina Boni

  • Wilson H Miller

  • Charu Aggarwal

  • Martin Stern

  • Olivera Cirovic

  • Barbara Romagnoli

  • Randolph Christen

  • Raksha Dodia

  • Kevin Smart

  • Bernhard Reis

  • Nicolas Staedler

  • Carl Watson

  • Neeltje Steeghs

Medical Centers

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Rigshospitalet, Copenhagen, Denmark

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Saint Louis Hospital, APHP, Paris, France

  • START Madrid, CIOCC, Madrid, Spain

  • Jewish General Hospital, Montreal, QC, Canada

  • University of Pennsylvania, Philadelphia, PA

  • Roche Innovation Center Zurich, Schlieren, Switzerland

  • Roche Innovation Center Basel, Basel, Switzerland

  • Roche Innovation Center Welwyn, Welwyn Garden City, UK

  • A4P Consulting Ltd, Sandwich, UK

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

Locations

  • France

  • Netherlands

  • Denmark

  • Spain

  • Canada

  • United States

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Non Small Cell Lung cancer

  • Small cell lung cancer

  • Squamous cell carcinoma

  • Solid malignancies

  • Colorectal Cancer

  • Lung Cancer

Biomarkers

  • Cluster of Differentiation 40

Drug/Treatment

  • Atezolizumab

  • Selicrelumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Fixed Dose

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved